<DOC>
	<DOCNO>NCT02736409</DOCNO>
	<brief_summary>This multicenter , double- blind extension study Oral Budesonide Suspension ( OBS ) adult adolescent ( 11 55 year age , inclusive ) Eosinophilic Esophagitis ( EoE ) complete participation SHP621-301 induction study ( NCT02605837 ) . The primary objective evaluate maintenance efficacy OBS 36 week . Maintenance efficacy measure peak eosinophilic count Dysphagia Symptom Questionnaire ( DSQ ) score .</brief_summary>
	<brief_title>An Extension Study Evaluate Maintenance Efficacy Long-term Treatment Effect Oral Budesonide Suspension ( OBS ) Adults Adolescents With Eosinophilic Esophagitis ( EoE )</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1 . Subject complete SHP621301 induction study . 2 . Subject able provide write informed consent ( subject , parent legal guardian , appropriate , subject assent ) participate study complete studyrelated procedure . 3 . Subject male female age 1155 year , inclusive , time consent SHP621301 study . 4 . Subject willing able continue dietary therapy , environmental therapy , and/or medical regimen ( include gastric acid suppression ; see exclusion ) effect screen visit ( Visit 0 ) . There change regimen study participation . 5 . All female subject must negative serum pregnancy test ( betahuman chorionic gonadotropin [ βhCG ] ) prior enrollment study . Females childbearing potential must agree continue acceptable birth control measure ( eg , abstinence , stable oral contraceptive , doublebarrier method ) throughout study participation 30 day follow last dose investigational product . 6 . Subject willing understanding ability fully comply study procedure include DSQ compliance ( complete DSQ ≥70 % day 2 consecutive week screen period ) restriction define protocol 1 . Subject change medication could affect study diet week since final treatment evaluation visit ( Visit 4 ) SHP621301 study . 2 . Subject use immunomodulatory therapy since final treatment evaluation visit ( Visit 4 ) SHP621301 study anticipate use immunomodulatory therapy treatment period ( except ongoing regimen allergy shot ) ; temporary use ( ≤7 day ) initiation new steroid treatment study document discussed medical monitor prospectively occur within 4 week schedule EGDs . 3 . Subject use swallowed topical corticosteroid EoE systemic corticosteroid condition since final treatment evaluation visit ( Visit 4 ) SHP621301 study anticipate use treatment period ; temporary use ( ≤7 day ) initiation new steroid treatment study document discussed medical monitor prospectively occur within 4 week schedule EGDs . 4 . Subject inhale intranasal steroid stable dose baseline visit ( Visit 1 ) SHP621301 study screen EGD study . 5 . Subject initiate , discontinue , change dosage regimen proton pump inhibitor ( PPIs ) , H2 antagonists , antacid , antihistamine , leukotriene inhibitor condition ( gastroesophageal reflux disease , asthma allergic rhinitis ) since final treatment evaluation visit ( Visit 4 ) SHP621301 study anticipate change use medication treatment period . 6 . Subject use Cytochrome P450 3A4 inhibitor ( eg , ketoconazole , grapefruit juice ) since final treatment evaluation visit ( Visit 4 ) SHP621301 study anticipate use medication treatment period . 7 . Subject appearance screen EGD esophageal stricture ( high grade ) , define presence lesion allow passage diagnostic adult upper endoscope ( eg , insertion tube diameter &gt; 9mm ) . 8 . Subject pure liquid diet sixfood elimination diet . 9 . Subject presence esophageal varix EGD final treatment evaluation visit ( Visit 4 ) SHP621301 study . 10 . Subject current disease gastrointestinal tract , aside EoE , include eosinophilic gastritis , enteritis , colitis , proctitis , inflammatory bowel disease , celiac disease . 11 . Subject diseases cause associate esophageal eosinophilia , include hypereosinophilic syndrome , collagen vascular disease , vasculitis , achalasia , parasitic infection . 12 . Subject oropharyngeal esophageal candidiasis fail respond previous treatment . Diagnosis oropharyngeal esophageal candidiasis since final treatment evaluation visit ( Visit 4 ) SHP621301 study exclusion long subject receive treatment candidiasis expect respond treatment . 13 . Subject acute chronic infection immunodeficiency condition , include tuberculosis , fungal , bacterial , viral/parasite infection , ocular herpes simplex , chicken pox/measles . 14 . Subject upper gastrointestinal bleeding identify EGD final treatment evaluation visit ( Visit 4 ) SHP621301 study since final treatment evaluation visit ( Visit 4 ) SHP621301 study . 15 . Subject evidence active infection Helicobacter pylorus . 16 . Subject evidence unstable asthma since final treatment evaluation visit ( Visit 4 ) SHP621301 study . 17 . Subject female pregnant nursing . 18 . Subject history intolerance , hypersensitivity , idiosyncratic reaction budesonide ( corticosteroid ) , ingredient study medication . 19 . Subject history high risk noncompliance treatment regular clinic visit . 20 . Subject sucralfate anticipates use sucralfate treatment period .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>